EUVIMEDEUVIMED entdecken
Open Access

Hyperactivation of the JAK2/STAT5 Signaling Pathway and Evaluation of Baricitinib Treatment Among Patients With Eosinophilic Cellulitis

Johanna Morot, Ester Del Duca, Marine Chastagner, Marie Fernandes, Yeriel Estrada, Marine-Alexia Lefevre, Jean Kanitakis, Olivier Harou, Denis Jullien, Jean-Francois Nicolas, James G Krueger, Marc Vocanson und 2 weitere

JAMA Dermatology · 2023

DOI: 10.1001/jamadermatol.2023.1651 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Dermatology, 2023. Verfasst von Johanna Morot und 13 weiteren Autor:innen. Beteiligte Einrichtung: Centre International de Recherche en Infectiologie, Université Claude Bernard Lyon 1, Inserm U1111, CNRS, UMR5308, ENS Lyon, Lyon, France. Hauptthemen laut MEDLINE: STAT5 Transcription Factor, Signal Transduction. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance The pathogenesis of eosinophilic cellulitis (EC) is poorly understood, limiting available treatment options. The current treatment paradigm focuses on delayed type 2 hypersensitivity reaction to various triggers.

Objective

To gain further insight into the nature of EC inflammation and into the cellular signal transduction pathways that are activated in the context of EC. Design, Setting, and Participants This case series was conducted in Lyon, France, from January 2018 to December 2021. Analysis of archival skin biopsy samples from patients with EC and from healthy control participants was performed using histology, Janus kinase (JAK)–signal transducer and activator of transcription (STAT) immunohistochemistry, and gene profiling. Data analysis was conducted between January 2020 and January 2022. Main Outcomes and Measures Pruritus (visual analog score), percentage of body surface area with lesional skin, and RNA transcripts of inflammatory biomarkers from the skin (threshold cycle) were assessed in 1 index patient with refractory EC who received oral JAK1/JAK2 inhibitor baricitinib (4 mg/d).

Results

This study included samples from 14 patients with EC (7 men and 7 women) and 8 healthy control participants (4 men and 4 women). The mean (SD) age of patients was 52 (20) years. Marked type 2 inflammation (chemokines CCL17, CCL18, and CCL26 and interleukin 13) with preferential activation of the JAK1/JAK2–STAT5 pathways in EC lesions was observed. In the 1 index patient with refractory EC, complete clinical remission of skin lesions was observed after 1 month of treatment with baricitinib. Conclusions and Relevance These findings suggest that EC is a type 2 inflammatory disease with preferential activation of the JAK1/JAK2-STAT5 pathways. In addition, these results suggest the potential of treatment approaches targeting JAK1/JAK2 for patients with EC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

STAT5 Transcription FactorSignal TransductionAdultMaleFemaleJanus Kinase 1AgedMiddle AgedInflammationJanus Kinase 2HumansAzetidinesPurinesPyrazolesSulfonamidesCellulitisEosinophilia

Substanzen

STAT5 Transcription FactorJanus Kinase 1Janus Kinase 2baricitinibAzetidinesPurinesPyrazolesSulfonamidesJAK2 protein, human

Autor:innen und Institutionen

  • Centre International de Recherche en Infectiologie, Université Claude Bernard Lyon 1, Inserm U1111, CNRS, UMR5308, ENS Lyon, Lyon, France.
  • Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai Hospital, New York, New York.
  • Department of Dermatology, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France.
  • Department of Pathology, Hôpital Lyon-Sud, Hospices Civils de Lyon, Pierre-Bénite, France.
  • Department of Allergology and Immunology, Hôpital Lyon-Sud, Hospices Civils de Lyon, Pierre-Bénite, France.
  • Laboratory of Investigative Dermatology, The Rockefeller University, New York, New York.

Zitieren

APA

Morot, J., Del Duca, E., Chastagner, M., Fernandes, M., Estrada, Y., Lefevre, M. A., Kanitakis, J., Harou, O., Jullien, D., Nicolas, J. F., Krueger, J. G., Vocanson, M., Guttman-Yassky, E., & Villani, A. P. (2023). Hyperactivation of the JAK2/STAT5 Signaling Pathway and Evaluation of Baricitinib Treatment Among Patients With Eosinophilic Cellulitis. JAMA Dermatology. https://doi.org/10.1001/jamadermatol.2023.1651

Vancouver

Morot J, Del Duca E, Chastagner M, Fernandes M, Estrada Y, Lefevre MA, et al. Hyperactivation of the JAK2/STAT5 Signaling Pathway and Evaluation of Baricitinib Treatment Among Patients With Eosinophilic Cellulitis. JAMA Dermatology. 2023. doi:10.1001/jamadermatol.2023.1651

BibTeX
@article{Morot2023,
  author = {Morot, Johanna and Del Duca, Ester and Chastagner, Marine and Fernandes, Marie and Estrada, Yeriel and Lefevre, Marine-Alexia and Kanitakis, Jean and Harou, Olivier and Jullien, Denis and Nicolas, Jean-Francois and Krueger, James G and Vocanson, Marc and Guttman-Yassky, Emma and Villani, Axel P},
  title = {Hyperactivation of the JAK2/STAT5 Signaling Pathway and Evaluation of Baricitinib Treatment Among Patients With Eosinophilic Cellulitis},
  journal = {JAMA Dermatology},
  year = {2023},
  doi = {10.1001/jamadermatol.2023.1651}
}
Kostenlos starten →